

ORIGINAL ARTICLE

Airways Disease

Early molecular biomarkers predicting the evolution of allergic rhinitis and its comorbidities: A longitudinal multicenter study of a patient cohort

Francesca Cipriani¹  | Salvatore Tripodi² | Valentina Panetta^{3,4} | Serena Perna⁴ | Ekaterina Potapova⁴ | Arianna Dondi^{4,5} | Roberto Bernardini⁶ | Carlo Caffarelli⁷ | Antonella Casani⁸ | Rosa Cervone⁶ | Loredana Chini⁹ | Pasquale Comberiati^{10,11} | Giovanna De Castro¹² | Michele Miraglia Del Giudice¹³ | Iride Dello Iacono¹⁴ | Andrea Di Rienzo Businco² | Marcella Gallucci¹ | Arianna Giannetti¹ | Carla Mastroianni^{4,7}  | Viviana Moschese⁹ | Simone Pelosi¹⁵ | Ifigenia Sfika² | Elena Varin¹⁶ | Valeria Vilella² | Anna Maria Zicari¹² | Giulia Brindisi¹² | Giampaolo Ricci¹  | Paolo Maria Matricardi⁴  |
for the Italian Pediatric Allergy Network (I-PAN)

¹Pediatric Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy

²Pediatric Department and Pediatric Allergology Unit, Sandro Pertini Hospital, Rome, Italy

³Consultancy & Training, Biostatistics, L'altrastatistica srl, Rome, Italy

⁴Department of Pediatric Pneumology and Immunology, Charite Medical University, Berlin, Germany

⁵Pediatric Emergency Unit, S. Orsola-Malpighi Hospital, Bologna, Italy

⁶Pediatric Unit, San Giuseppe Hospital, Empoli, Italy

⁷Clinica Pediatrica, Department of Medicine and Surgery, University of Parma, Parma, Italy

⁸Pediatra di Libera Scelta, Benevento, Italy

⁹UOSD di Immunopatologia ed Allergologia Pediatrica, Policlinico Tor Vergata, Università di Roma Tor Vergata, Rome, Italy

¹⁰Department of Clinical and Experimental Medicine, Section of Paediatrics, University of Pisa, Pisa, Italy

¹¹Department of Clinical Immunology and Allergology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia

¹²Pediatric Department, La Sapienza University, Rome, Italy

¹³Dipartimento della Donna, del Bambino e di Chirurgia Generale e Specialistica, Università della Campania Luigi Vanvitelli, Naples, Italy

¹⁴Pediatric Unit, Fatebenefratelli Hospital, Benevento, Italy

¹⁵TPS Production, Rome, Italy

¹⁶Pediatric Intermediate Care Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

Correspondence

Giampaolo Ricci, Pediatric Unit, Department of Medical and Surgical Sciences, S. Orsola Malpighi Hospital, University of Bologna, Bologna, Italy.
Email: giampaolo.ricci@unibo.it

Edited by: Ömer Kalayci

Abstract

Background: Pollen-related seasonal allergic rhinoconjunctivitis (SAR) is a very frequent pediatric disease in Westernized countries. Risk factors and disease phenotypes have been thoroughly examined in several cross-sectional studies. By contrast, only a few studies have examined disease evolution in patient cohorts. We investigated predictive biomarkers of disease evolution in a large cohort of children with SAR.

Methods: During 2015-2017 (follow-up), we re-examined 401 patients from those enrolled in 2009-2011 (baseline) by the “Panallergens in Pediatrics” study, a large multicenter survey of Italian children with SAR. Information on clinical history (standard questionnaire, AllergyCARD®; TPS, Italy) and skin prick tests for inhalant and foods extracts (ALK-Abelló, Hørsholm, Denmark) was acquired as at baseline visit. Evolution in clinical and sensitization data of patients was analyzed over time, as well as their association with the main baseline characteristics and atopy risk factors.

Results: The average age of participants was 10.4 ± 3.4 years at baseline and 16.2 ± 3.6 years at follow-up. SAR persisted in 93.3% of patients at follow-up and became more frequently associated with asthma (from 36.7% at baseline to 48.6% at follow-up) and oral allergy syndrome (OAS, from 23.4% to 37.7%). Compared to baseline, the prevalence of skin sensitization to some pollens (*Phleum pratense*, *Corylus avellana*, *Platanus acerifolia*, *Artemisia vulgaris*) and vegetables (hazelnut, wheat, and apple) significantly decreased at follow-up. Earlier onset of SAR and polysensitization at baseline were associated with incident asthma at follow-up. The presence at baseline of serum IgE to the following allergen molecules was identified as biomarkers of clinical evolution: (a) Phl p 1, for persistence of SAR; (b) Phl p 5, for persistence of both rhinitis and asthma; (c) Pru p 3, for new onset of asthma; (d) Bet v 1, for persistence of OAS.

Conclusions: Seasonal allergic rhinoconjunctivitis is clinically heterogeneous in its evolution from childhood to adolescence. The detection of serum IgE to specific molecules (Phl p 1, Phl p 5, Bet v 1, Pru p 3) may be useful as biomarkers to predict SAR persistence and future onset of comorbidities, such as asthma and/or OAS.

KEYWORDS

allergic rhinitis, asthma, Bet v 1, biomarkers, children, comorbidities, IgE, longitudinal study, Phl p 1, Phl p 5, pollen, prediction, Pru p 3

1 | INTRODUCTION

Seasonal allergic rhinoconjunctivitis (SAR) induced by pollens (pollen-induced SAR) affects millions of people globally, with a particularly relevant prevalence in the pediatric age and high social and economic burden.^{1,2} The severity of SAR, its association with other allergic conditions (eg, asthma, oral allergy syndrome—OAS), and its response to pharmacotherapy and to allergen immunotherapy (AIT) can be widely different among patients.³ “Panallergens in Pediatrics” study (PAN-PED) was the first nationwide observational multicenter survey carried out by the I-PAN group with the aim to investigate the impact of sensitization to highly cross-reacting allergenic molecules on the diagnostic and therapeutic management of respiratory allergies in childhood.^{4,5} The baseline study recruited 1360 children affected by pollen-induced AR who had never undergone AIT in 16 pediatric outpatient clinics between May 2009 and June 2011. Patients' clinical features and allergic sensitization have been widely described in the previous articles.⁶⁻¹¹ In those suffering from grass pollen-induced SAR, we showed a wide heterogeneity of molecular IgE sensitization profiles to *Phleum pratense*, and we identified three

Key Message

In this study we investigated predictive biomarkers of disease evolution in a large cohort of children with seasonal allergic rhinoconjunctivitis (SAR). The clinical course of SAR and its comorbidities from infancy to adolescence is heterogeneous and we found that the detection at baseline of serum IgE to specific allergen molecules (Phl p 1, Phl p 5, Bet v 1 and Pru p 3) may be useful as biomarkers to predict SAR persistence and future onset of comorbidities, such as asthma and/or OAS.

main serological biomarkers: Phl p 1 as a marker of grass pollen allergy, Phl p 7 as a specific biomarker of asthma among SAR patients, and Phl p 12 as a stronger biomarker of OAS.¹¹ The usefulness of these biomarkers in the diagnostic workup of the child with grass pollen allergy needs to be tested in prospective studies of patient

cohorts. Meanwhile, the evolution of SAR and the progression of allergic sensitization in childhood are still lacking evidence and there are no validated or generally accepted candidate biomarkers to predict the clinical response to AIT.¹² The present study aimed at investigating the evolution of clinical features and allergic sensitization of the previously recruited patients of the PAN-PED cohort and analyzing their association with the main baseline characteristics of patients. The final target is therefore to identify potential predictive factors for clinical evolution of SAR.

2 | MATERIALS AND METHODS

2.1 | Study design and population

The prospective follow-up study (PAN-PED FU) was performed in 11 pediatric outpatient clinics from eight Italian cities in Northern Italy (Milan, Verona, Parma, and Bologna), Central Italy (Empoli and Rome), and Southern Italy (Naples and Benevento) between March 2015 and December 2017. Six of the original 16 recruiting centers (Genoa, Ascoli Piceno, Ostia, Crotone, Cagliari, Palermo) of the PAN-PED cohort did not participate in the present follow-up study. Criteria for eligibility to the original study (2009–2011) were as follows: (a) age 4–18 years; (b) a history of pollen-induced AR and/or asthma in one of the two last pollen seasons; (c) positive skin prick tests (SPTs) for the relevant pollen extracts. Criteria for eligibility to this follow-up study (2015–2017) were as follows: (a) participation to PAN-PED study in the years 2009–2011 and (b) signed informed consent, (c) absence of any other severe chronic disease. Recruited children's parents answered to a standardized questionnaire, and patients underwent skin prick tests (SPTs) and a blood sample collection, as for the baseline study. The PAN-PED FU study design and procedures have been approved by the ethical committee of S. Orsola-Malpighi Hospital of Bologna (103/2009/O/Oss, EM 178/2014/O and 210/2015/U) and of all the participating centers. Patients or their parents or tutors of all participants signed an informed consent before being involved in the clinical investigations.

2.2 | Questionnaire

An updated version of the electronic Clinical Record Form (e-CRF) already used at baseline (AllergyCARD®; Technology Projects & Software Productions [TPS], Rome, Italy) was used for data input and collection in the follow-up study. This new version of AllergyCARD included a standardized questionnaire to assess health-related quality of life (HRQoL),¹³ questions about pharmacotherapy drugs administered in the previous pollen season and its efficacy on symptoms, allergy related to lipid transfer protein (LTP) in patients who referred allergic reactions to peach, and information about AIT and its subjective efficacy on AR symptoms for patients who underwent AIT after the baseline study. Questionnaires were administered to all participants by well-trained physicians. A diagnosis of current pollen-induced AR was made in the presence of nasal and/or eye

symptoms (apart from cold) for at least 3 weeks during the last pollen seasons. The annual period of symptoms was defined as the months with symptoms in the 12 months preceding the recruitment visit. In presence of a doctor-diagnosed pollen-induced asthma, symptoms severity were classified according to Global Initiative for Asthma—GINA.¹⁴ Oral allergy syndrome (OAS) was defined as the occurrence of immediate oral itching with or without angioedema of the lips and/or the tongue following the ingestion of the food, as previously described.⁷ The presence of other allergic symptoms (doctor-diagnosed urticaria/angioedema, anaphylaxis, gastrointestinal symptoms) after food ingestion has been investigated in the last 5 years.

2.3 | Skin prick tests

Allergic sensitization was assessed by SPTs using the same panel of aeroallergens (*P pratense*, *Cynodon dactylon*, *Parietaria judaica*, *Plantago lanceolata*, *Chenopodium album*, *Artemisia vulgaris*, *Salsola kali*, *Ambrosia artemisiifolia*, *Cupressus arizonica*, *Betula verrucosa*, *Platanus acerifolia*, *Olea europea*, *Corylus avellana*), food allergens (peach, apple, wheat, soybean, peanut, hazelnut), profilin, and latex used in the previous study (ALK-Abelló, Hørsholm, Denmark). In addition, patients underwent SPT also for *Dermatophagoides pteronyssinus*, cat, and alternaria. Histamine dihydrochloride 10 mg/mL and glycerol saline solution were used as positive and negative controls, respectively. Morrow-Brown needles were used to prick the skin, and the wheal reactions were read after 15 minutes. A wheal ≥ 3 mm was regarded as positive.¹⁵

2.4 | Serological biomarkers at baseline

Serum total IgE levels and specific IgE (sIgE) levels to known panallergens (Phl p 7, Phl p 12, Bet v 1, Pru p 3), to the main *P pratense* molecular allergens (Phl p 1, Phl p 2, Phl p 4, Phl p 5, Phl p 6, Phl p 11) and to the perennial allergens *D pteronyssinus*, *Alternaria alternata*, and cat dander had been tested at baseline using a fluorescence enzyme immunoassay (FEIA) with capsulated cellulose polymer solid-phase (Immuno CAP®) coupled allergens (Thermo Fisher Scientific Inc, Phadia AB, Uppsala, Sweden). Results were expressed in kU/L, and a cutoff point of 0.35 kU/L has been used for positivity.

2.5 | Statistical analysis

Mean and standard deviation (SD) were used to summarize quantitative data and number of subject (n) and per cent (%) to summarize categorical data. Change in binomial data (presence of allergic symptoms, positivity at SPT) between baseline and follow-up was tested by McNemar test, and change in quantitative data was tested by paired t test. The analysis of predictive factors of clinical evolution of allergic rhinitis and its main comorbidities (asthma and OAS) was performed by grouping patients in several groups: (a) *persistent* if symptoms were present at both baseline and follow-up, (b) *remittent* if symptoms were present at baseline study but not at follow-up; (c)

absent if patient never had the symptoms, neither at baseline nor at follow-up (only for SAR comorbidities); (d) *incident* if patients had no symptoms at baseline but had them at follow-up (only for SAR comorbidities). We analyzed the correlation between the clinical evolution of AR, allergic asthma, and OAS and individual or aggregated serological biomarkers tested at baseline: total IgE levels, sIgE response to known panallergens (Phl p 12, Bet v 1, Pru p 3), sIgE response to the main *P pratense* molecular allergens, number of *P pratense* molecules recognized by IgE, sIgE to *D pteronyssinus*, *A alternata*, and cat dander. Several univariable logistic regressions were implemented to evaluate the impact of clinical predictor factors, SPT, sIgE, and symptoms evolution on rhinitis remission, asthma remission, asthma incident, OAS remission and OAS incidence, separately. Odds ratio (OR) and its 95% confidence interval were reported (CI 95%). SAS 9.4 was used for all analysis, and a *P* value <0.05 was considered statistically significant.

3 | RESULTS

3.1 | Clinical evolution of AR and its comorbidities

The study population included 401 patients (64.3% males) out of the 1024 (60.6% males) recruited by the 11 participating centers in the baseline study in the "PAN-PED" project (Table 1). Patients participating in the follow-up study had higher familial atopy from the father's side, and an increase in other food-related allergic symptoms, particularly urticaria/angioedema and gastrointestinal symptoms, than those not participating at the follow-up study (Table S1). The mean age was 10.4 ± 3.4 years at baseline and 16.2 ± 3.6 years at follow-up. At baseline, all the patients were suffering from AR, 36.7% of them had asthma, 23.4% oral allergy syndrome (OAS), and 32.2% other food-related allergic symptoms (Table 1). AR persisted at follow-up in 93.3% of patients, whose symptoms period within

	Baseline N = 401	Follow-up N = 401	<i>P</i> value
Males (n, %)	258 (64.3)		
Age (y) (mean, SD)	10.4 (3.4)	16.2 (3.6)	
Geographic area of Italy			
North (n, %)	193 (48.1)		
Center (n, %)	142 (35.4)		
South (n, %)	66 (16.5)		
Familial atopy			
Father (n, %)	180 (44.9)		
Mother (n, %)	157 (39.2)		
Allergic rhinitis (n, %)	401 (100)	374 (93.3)	
Age at onset (y) (mean, SD)	5.2 (2.8)		
Months/years with symptoms (mean, SD)	4.1 (1.7)	4.2 (2.2)	
Asthma ^a (n, %)	147 (36.7)	195 (48.6)	
Remittent		33 (8.2)	<0.001
Persistent		114 (28.4)	
Incident		81 (20.2)	
Absent		173 (43.1)	
Oral allergy syndrome ^b (n, %)	94 (23.4)	151 (37.7)	
Remittent		31 (7.7)	<0.001
Persistent		63 (15.7)	
Incident		88 (21.9)	
Absent		219 (54.6)	
Other food-related allergic symptoms ^b (n, %)	129 (32.2)	94 (23.4)	0.001
Anaphylaxis (n, %)	21 (5.2)	21 (5.2)	1.000
Urticaria/angioedema (n, %)	93 (23.2)	72 (18.0)	0.046
Gastrointestinal symptoms (n, %)	41 (10.2)	39 (9.7)	0.789

TABLE 1 Characteristics of the population sample at baseline and follow-up

Statistically significant values (*P* value<0.05) were reported in bold.

^aDoctor-diagnosed asthma.

^bDoctor-diagnosed oral allergy syndrome or other food-related allergic symptoms.

a year did not significantly change. Compared to baseline, the prevalence of asthma (from 36.7% to 48.6%, $P < 0.001$) and OAS (from 23.4% to 37.7%, $P < 0.001$) significantly increased, while the prevalence of other food-related allergic symptoms significantly decreased (from 32.2% to 23.4%, $P = 0.001$). The overall increase in the prevalence of asthma at follow-up takes into account both cases of remissions and new onset of disease. In fact, among the 147 patients (36.7% of the whole sample) suffering from asthma at baseline, 33/147 (22.4%) experienced the remission of symptoms. Meanwhile, among the 254 patients without a diagnosis of asthma

at baseline, 81/254 (31.9%) developed asthma in the following years. Among the 94 patients (23.4% of the whole sample) suffering from OAS at baseline, 31 (33%) experienced the remission of symptoms; meanwhile, among the 307 without OAS at baseline, 88 (28.7%) developed OAS during the following years (Table 1).

3.2 | Evolution of atopic sensitization

The mean number of positive SPT reactions slightly but significantly decreased, from 5.4 ± 2.8 at baseline to 5.2 ± 2.8 at follow-up

TABLE 2 Atopic sensitization assessed by skin prick test to pollens and vegetable food allergens at baseline and follow-up in 401 patients included in the study

	Baseline		Follow-up			
Allergenic extract	%	Wheal (mm, SD)	%	Wheal (mm, SD)	P value [*]	P value ^{**}
Pollens						
<i>Phleum pratense</i>	93.0	7.0 ± 3.2	86.5	6.8 ± 2.6	<0.001	0.228
<i>Cynodon dactylon</i>	76.1	5.5 ± 2.4	75.3	5.8 ± 2.3	0.753	0.217
<i>Olea europea</i>	60.3	6.1 ± 3.0	62.1	6.1 ± 2.6	0.486	0.989
<i>Plantago lanceolata</i>	66.1	5.4 ± 2.8	68.1	5.7 ± 2.7	0.462	0.265
<i>Chenopodium album</i>	67.2	4.7 ± 1.9	54.6	4.9 ± 2.4	<0.001	0.341
<i>Cupressus arizonica</i>	37.7	5.2 ± 2.2	45.9	5.8 ± 2.2	<0.001	0.017
<i>Betula verrucosa</i>	41.1	5.0 ± 1.8	39.2	5.1 ± 1.9	0.419	0.632
<i>Platanus acerifolia</i>	37.9	4.8 ± 2.1	31.7	5.0 ± 2.4	0.017	0.529
<i>Parietaria judaica</i>	30.4	5.9 ± 2.8	29.2	6.3 ± 2.7	0.541	0.281
<i>Corylus avellana</i>	46.7	2.2 ± 2.5	38.2	2.0 ± 2.4	0.03	0.268
<i>Artemisia vulgaris</i>	27.2	4.8 ± 2.1	20.7	4.9 ± 1.7	0.009	0.753
<i>Salsola kali</i>	29.2	4.1 ± 1.5	27.2	4.4 ± 2.6	0.424	0.432
<i>Ambrosia artemisiifolia</i>	21.4	4.1 ± 1.7	26.9	4.3 ± 1.5	0.168	0.458
All (mean, SD) ^a		5.4 ± 2.8		5.2 ± 2.8	0.021	
Monosensitized	7.8		6.2		0.304	
2-4 pollen ^a	33.1		35.9		0.169	
>4 pollen ^a	59.2		55.9		0.107	
>6 pollen ^a	35.8		32.2		0.043	
Vegetable foods						
Peanut	31.4	4.7 ± 2.7	30.2	5.1 ± 2.8	0.629	0.232
Hazelnut	29.4	4.9 ± 2.2	20.4	4.9 ± 2.9	<0.001	0.859
Peach	17.5	5.3 ± 2.4	15.7	6.1 ± 2.3	0.336	0.048
Wheat	23.7	6.5 ± 3.0	7.5	3.9 ± 1.6	<0.001	0.003
Apple	13.5	5.4 ± 2.3	9.7	5.1 ± 1.8	0.032	0.565
Soybean	8.5	4.2 ± 1.5	5.2	4.5 ± 1.5	0.058	0.555
>3 foods	10.7		7.0		0.016	
Profilin	31.2	5.8 ± 2.4	30.4	5.6 ± 2.0	0.736	0.548
Latex	1.1	3.6 ± 0.9	3.5	4.4 ± 3.7	0.206	0.678

Statistically significant values (P value < 0.05) were reported in bold.

^aSkin reactions to pollens (wheal ≥ 3 mm). SPT extracts included the following: grass pollen (*P pratense* or *C dactylon*), *B verrucosa*, *C arizonica*, *P acerifolia*, *O europaea*, *P judaica*, Compositae pollen (*A vulgaris* or *A artemisiifolia*), *P lanceolata*, *S kali*, *C avellana*, and *C album*.

* P value is referred to the percentage of patients with wheal diameter ≥ 3 mm, except for ^a that are referred to mean number of positive SPT.

** P value is referred to mean value and is calculated by mixed model taking into account that some patients are the same at baseline and at follow up and some not.




FIGURE 1 Predictive factors of allergic rhinitis remission in 401 Italian children with pollen allergy (univariate analysis)

($P = 0.021$). In particular, sensitization to *P pratense*, *C album*, *P acerifolia*, *C avellana*, *A artemisiifolia* and the prevalence of highly polysensitized patients decreased at follow-up (Table 2). Similarly, sensitization to food allergens, in particular for hazelnut, wheat, and apple, remarkably decreased at follow-up. In contrast, the prevalence of sensitization to cat (from 34.9% to 45.1%, $P < 0.001$) significantly increased at follow-up (Table S2). Overall, no variations in the prevalence of patients with 4 or more positive SPTs to indoor and/or pollen allergens were observed (Table 2).

3.3 | Predictive biomarkers of clinical evolution

We analyzed the association and predictive value of biomarkers of atopic sensitization at baseline and the clinical evolution (persistence/remission and new onset) of (A) allergic rhinitis, (B) asthma, and (C) oral allergic syndrome (OAS).

- **Predictive biomarkers of persistent or remittent AR**—Polysensitization to pollen and indoor allergens, a positive SPT to grass pollen, and genuine sensitization to Phl p 1 and to Phl p 5 were all significantly associated with persistence of AR at follow-up (Figure 1, Table S3). By contrast, gender, age at onset, yearly duration of symptoms, and asthma- or OAS-comorbidity at baseline were not associated with remission or persistence of AR symptoms at follow-up (Figure 1, Table S3).
- **Predictive biomarkers of persistent or incident asthma**—Persistence of asthma at follow-up was weakly, but significantly associated with a higher spreading of the slgE response to *P pratense* molecules at baseline, and with a higher prevalence of sensitization to Phl p 5 (Figure 2, Table S4). Incident asthma was instead associated with an earlier onset of AR symptoms, a higher number of positive slgE responses to indoor allergens and polysensitization to airborne allergens in general, higher total IgE levels and presence of slgE to Pru p 3 at baseline (Figure 2, Table S4).
- **Predictive biomarkers of persistent or incident OAS**—Persistence of oral allergy syndrome (OAS) was associated with female gender, with a longer duration of AR symptoms, asthma at baseline and with IgE sensitization to Bet v 1 at baseline (Figure 3A, Table S5). Incident OAS at follow-up was associated with polysensitization to airborne allergens (Figure 3B, Table S5).

4 | DISCUSSION

This longitudinal, prospective study examined the clinical evolution of seasonal allergic rhinitis and its predictors in 401 Italian pediatric patients followed up for about 6 years. To our knowledge, this is one of the few studies identifying various biomarkers of AR remission and of incident or persistent asthma and OAS in children with seasonal allergic rhinitis.

4.1 | Absence of slgE to Phl p 1 predicts AR remission

We found an extremely low rate (only 7%) of AR remission at follow-up. A lower atopic status and the absence of slgE sensitization to the major *P pratense* molecular allergens Phl p 1 were found to be associated with remission of AR at follow-up. Phl p 1 is a marker of genuine sensitization to grass pollen^{16,17} and by far the most important initiator of grass pollen allergy. We^{6,11} and others¹⁸ have already shown that grass pollen-allergic patients are rarely not sensitized to Phl p 1. The present study adds that the lack of slgE to Phl p 1, an infrequent condition also in this patient cohort, is a predictor of remission of grass pollen allergy in Italian children.

4.2 | Predictors of persistent or incident asthma

In our patient cohort, a bigger molecular spreading of *P pratense* IgE responses combined with higher IgE to Phl p 5 at baseline was




FIGURE 2 Predictive factors of asthma (A) remission and (B) new onset in 401 Italian children with pollen allergy (univariate analysis)

associated with persistent asthma. Phl p 5 is a less common sensitizing agent in grass pollen-allergic patients than Phl p 1.¹⁷ However, IgE to this molecule provokes stronger degranulation of mast cells and basophils¹⁹ and has been already associated with more severe disease and asthma.²⁰

Higher total IgE levels, polysensitization to airborne allergens, IgE to indoor allergens and to Pru p 3 were associated with incident asthma at follow-up. A later onset age of AR was found to be associated with a lower risk to develop asthma, independently of patient's atopic status, and confirmed by multivariate analysis. Most of these associations just confirm remote or recent observations. A higher degree of atopic sensitization,²¹⁻²³ sensitization to mites and other indoor or perennial allergens,^{21,23,24} and higher total IgE²⁵⁻²⁷ are all independent predictors of asthma. A recent population-based birth cohort study identified different cross-sectional sensitization

patterns and their longitudinal trajectories²⁸. The strongest predictor of asthma at age 16 was IgE sensitization to dust mite molecules, while the strongest early-life predictor of subsequent asthma was IgE sensitization to grass/cat molecules. In the MAS birth cohort study, a higher spreading of IgE sensitization to a comprehensive panel of *D pteronyssinus* allergenic molecules was associated with asthma.²⁹ This study has also revealed that earlier onset of IgE sensitization to indoor allergens is a predictor of incident asthma.²⁹

Interestingly, the present study adds slgE to Pru p 3 to the long list of asthma predictors in children with seasonal allergic rhinitis. Pru p 3 is a lipid transfer protein (LTP), and it is a marker of food allergy and higher risk of anaphylactic reactions.^{30,31} IgE sensitization to other nonspecific lipid transfer proteins (nsLTPs), such as Art v 3 and Pla a 3 (mugwort and plane tree nsLTPs, respectively), has been associated with respiratory symptoms in nsLTP-positive patients.³²




FIGURE 3 Predictive factors of oral allergy syndrome for (A) remission and (B) new onset in 401 Italian children with pollen allergy (univariate analysis)

Our study cannot discriminate whether IgE sensitization to Pru p 3 is causally associated with asthma or is simply a useful proxy of more severe atopic propensity, which in turn is causally associated with allergic inflammation of the lower airways and asthma. This question deserves further investigation.

4.3 | Predictors of persistent or incident oral allergy syndrome

Specific IgE to Bet v 1 at baseline was associated with persistent or incident OAS at follow-up. slgE to Bet v 1 is a well-known qualitative and quantitative marker of OAS.³³⁻³⁵ In the Swedish BAMSE cohort study, Bet v 1 was identified as a risk molecule, and as the most prevalent PR-10 protein, with higher amount of specific IgE.^{23,36} The sensitization to this molecule in early childhood was associated with severe allergic rhinitis to birch pollen at 16 years of age and

with OAS.³⁶ Another interesting outcome of our study was the association of asthma at baseline with persistent OAS. Moreover, both persistent asthma and persistent OAS were associated with polysensitization to airborne allergens at baseline. Together, these data suggest the presence of a cluster of children with polysensitization and allergy multimorbidity, that is, atopic disease affecting the upper and lower airways and the oral cavity. A similar phenotype has been recently described in a broader study of Garcia-Aymerich et al³⁷ from the MEDALL study group.

On the other hand, the prevalence of positive skin wheal reactions to wheat, hazelnut, and apple extracts declined over years in our study population, while the prevalence of OAS increased, especially in subjects with slgE to Bet v 1 at baseline. This outcome leads to hypothesize that the diagnostic and predictive value of in vitro assays defined at molecular level is much higher than that of in vivo SPT performed with vegetable food extracts. We are currently investigating

this hypothesis that has been also addressed by a recent study in a pediatric population of Spanish children.³⁸ The BAMSE cohort study has shown that, though general IgE sensitization to foods decreases between childhood and adolescence, the sensitization to plant food allergens remains analogous, while milk and egg sensitization decreases.³⁹ The Tucson cohort study also reported a high rate of remission of skin sensitization to many allergens during adolescence.⁴⁰ Therefore, our study is further reinforcing the concept that the evolution of IgE responses from childhood to adolescence is a very dynamic process characterized by new sensitization and remissions generating a great variety of IgE sensitization profiles at population levels in different ages.^{6,39,40}

4.4 | Limitations

We have to acknowledge some limitations of our study. First, our study population is a subset of a population of Italian pollen-allergic children. The generalizability of our outcomes to populations of different ages and geographic areas is therefore questionable. Second, for economic reasons, we have chosen to examine IgE sensitization to a few, although relevant, allergen molecules with a singleplex approach, while a broader evaluation with a microarray would have been more informative. Third, this longitudinal study is based on two time points only, so that our analysis is limited in its power and we cannot say how stable are the phenotypes observed at baseline in 2009-2011 and at follow-up in 2015-2017.

5 | CONCLUSIONS

The present follow-up study highlighted the heterogeneous clinical course of SAR and its comorbidities from childhood to adolescence and adulthood. The evidence of a low rate of AR remission and a significant increase in AR comorbidities at follow-up remarks the importance to find predictive biomarkers of clinical evolution. The detection of serum sIgE to Phl p 1, Phl p 5, Pru p 3, and Bet v 1 can be useful as clinical biomarkers for evolution of SAR and its comorbidities.

ACKNOWLEDGMENTS

We thank ALK-Abelló and Thermo Fisher Scientific (TFS) for providing the reagents for the study and TPS Production for the informatics platform AllergyCARD.

CONFLICT OF INTEREST

S. Tripodi has received a lecture fee from Thermo Fisher Scientific (Phadia), and he is cofounder of TPS Production. A. Dondi has received consultancy fees from Charité University Hospital, Berlin, Germany. C. Mastrorilli has received fellowship from Italian Society of Pediatrics. G. Ricci has received a grant from Thermo Fisher Scientific (Phadia) for research support. P. M. Matricardi has

received research support from TFS and lecture fees from TFS and Allergopharma. The rest of the authors declare that they have no relevant conflicts of interest.

AUTHOR CONTRIBUTION

GR, PMM, ST, and FC contributed to the conception and design of the study. FC, ST, SP, AD, RB, CC, AC, RC, LC, PC, GDC, MMDG, IDI, ADRB, MG, AG, CM, VM, SP, IS, EV, VV, AMZ, GB, and GR contributed to the acquisition of data. VP and FC performed the statistical analysis of data under the supervision of PMM. FC, VP, EK, and PMM contributed to the interpretation of the results and in drafting the manuscript. All authors revised and approved the final version of the manuscript.

ORCID

Francesca Cipriani  <https://orcid.org/0000-0002-2229-5263>

Carla Mastrorilli  <https://orcid.org/0000-0003-2481-7229>

Giampaolo Ricci  <https://orcid.org/0000-0002-3660-8750>

Paolo Maria Matricardi  <https://orcid.org/0000-0001-5485-0324>

REFERENCES

1. Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. *Lancet*. 2006;368:733-743.
2. Davies JM. Grass pollen allergens globally: the contribution of sub-tropical grasses to burden of allergic respiratory diseases. *Clin Exp Allergy*. 2014;44:790-801.
3. Darsow U, Brockow K, Pfab F, et al. Heterogeneity of molecular sensitization profiles in grass pollen allergy-implications for immunotherapy? *Clin Exp Allergy*. 2014;44:778-786.
4. Tozzi AE, Armenio L, Bernardini R, et al. Pediatric allergy and immunology in Italy. *Pediatr Allergy Immunol*. 2011;22:267-276.
5. Baldini M, Bernardini R, Berti I, et al. L'Italian pediatric allergy network: un'opportunità di ricerca per i clinici. *Riv Immunol Allergol Pediatr*. 2010;1:32-33.
6. Tripodi S, Frediani T, Lucarelli S, et al. Molecular profiles of IgE to *Phleum pratense* in children with grass pollen allergy: implications for specific immunotherapy. *J Allergy Clin Immunol*. 2012;129:834-839.
7. Dondi A, Tripodi S, Panetta V, et al. Pollen-induced allergic rhinitis in 1360 Italian children: comorbidities and determinants of severity. *Pediatr Allergy Immunol*. 2013;24:742-751.
8. Stringari G, Tripodi S, Caffarelli C, et al. The effect of component-resolved diagnosis on specific immunotherapy prescription in children with hay fever. *J Allergy Clin Immunol*. 2014;134:75-81.
9. Asero R, Tripodi S, Dondi A, et al. Prevalence and clinical relevance of IgE sensitization to profilin in childhood: a multicenter study. *Int Arch Allergy Immunol*. 2015;168:25-31.
10. Mastrorilli C, Tripodi S, Caffarelli C, et al. Endotypes of pollen food syndrome in children with seasonal allergic rhinoconjunctivitis: a molecular classification. *Allergy*. 2016;71:1181-1191.
11. Cipriani F, Mastrorilli C, Tripodi S, et al. Diagnostic relevance of IgE sensitization profiles to eight recombinant *Phleum pratense* molecules. *Allergy*. 2018;73:673-682.
12. Shamji Mh, Kappen Jh, Akdis M, et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic

- rhinoconjunctivitis and allergic asthma: an EAAI position paper. *Allergy*. 2017;72:1156-1173.
13. La Grutta S, Landi M, Braido F, et al. RHINASTHMA-adolescents: a new quality of life tool for patients with respiratory allergy. *Pediatr Allergy Immunol*. 2014;25:450-455.
 14. Bousquet J, Clark T, Hurd S, et al. GINA guidelines on asthma and beyond. *Allergy*. 2007;62:102-112.
 15. Bousquet J, Heinzerling L, Bachert C, et al. Practical guide to skin prick tests in allergy to aeroallergens. *Allergy*. 2012;67:18-24.
 16. Hatzler L, Panetta V, Lau S, et al. Molecular spreading and predictive value of preclinical IgE response to *Phleum pratense* in children with hay fever. *J Allergy Clin Immunol*. 2012;130:894-901.
 17. Douladiris N, Garib V, Tejkl MF, Valenta R, Papadopoulos NG, Linhart B. Detection of genuine grass pollen sensitization in children by skin testing with a recombinant grass pollen hybrid. *Pediatr Allergy Immunol*. 2019;30:59-65.
 18. Darsow U, Brockow K, Pfab F, et al. Heterogeneity of molecular sensitization profiles in grass pollen allergy—implications for immunotherapy? *Clin Exp Allergy*. 2014;44:778-786.
 19. Göbl C, Focke-Tejkl M, Najafi N, et al. Flexible IgE epitope containing domains of Phl p 5 cause high allergenic activity. *J Allergy Clin Immunol*. 2017;140:1187-1191.
 20. Sekerkova A, Polackova M, Striz I. Detection of Phl p 1, Phl p 5, Phl p 7 and Phl p 12 specific IgE antibodies in the sera of children and adult patients allergic to phleum pollen. *Allergol Int*. 2012;61:339-346.
 21. Lau S, Matricardi PM, Wahn U, Lee YA, Keil T. Allergy and atopy from infancy to adulthood: messages from the German birth cohort MAS. *Ann Allergy Asthma Immunol*. 2019;122:25-32.
 22. Matricardi PM, Nisini R, Biselli R, D'amelio R. Evaluation of the overall degree of sensitization to airborne allergens by a single serologic test: implications for epidemiologic studies of allergy. *J Allergy Clin Immunol*. 1994;93:68-79.
 23. Wickman M, Lupinek C, Andersson N, et al. Detection of IgE reactivity to a handful of allergen molecules in early childhood predicts respiratory allergy in adolescence. *EBioMedicine*. 2017;26:91-99.
 24. Illi S, von Mutius E, Lau S, et al. Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study. *Lancet*. 2006;368:763-770.
 25. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. *N Eng J Med*. 1989;320:271-277.
 26. Oettgen HC, Geha RS. IgE in asthma and atopy: cellular and molecular connections. *J Clin Invest*. 1999;104:829-835.
 27. Sacco O, Sale R, Silvestri M, et al. Total and allergen-specific IgE levels in serum reflect blood eosinophilia and fractional exhaled nitric oxide concentrations but not pulmonary functions in allergic asthmatic children sensitized to house dust mites. *Pediatr Allergy Immunol*. 2003;14:475-481.
 28. Howard R, Belgrave D, Papastamoulis P, Simpson A, Rattray M, Custovic A. Evolution of IgE responses to multiple allergen components throughout childhood. *J Allergy Clin Immunol*. 2018;142:1322-1330.
 29. Posa D, Perna S, Resch Y, et al. Evolution and predictive value of IgE responses toward a comprehensive panel of house dust mite allergens during the first 2 decades of life. *J Allergy Clin Immunol*. 2017;2:541-549.
 30. Mothes-Luksch N, Raith M, Stingl G, et al. Pru p 3, a marker allergen for lipid transfer protein sensitization also in Central Europe. *Allergy*. 2017;72:1415-1418.
 31. Perkins JR, Rodriguez MJ, Palomares MF, et al. Gene expression profiling of a Pru p 3-induced anaphylaxis model. *J Allergy Clin Immunol*. 2017;139:AB75.
 32. Scala E, Till SJ, Asero R, et al. Lipid transfer protein sensitization: reactivity profiles and clinical risk assessment in an Italian cohort. *Allergy*. 2015;70(8):933-943.
 33. Moverare R, Westritschning K, Svensson M, et al. Different IgE reactivity profiles in birch pollen-sensitive patients from six Europeans populations revealed by recombinant allergens: an imprint of local sensitization. *Int Arch Allergy Immunol*. 2002;128:325-335.
 34. Ciprandi G, Comite P, Ferrero F, et al. Birch allergy and oral allergy syndrome: the practical relevance of serum immunoglobulin E to Bet v 1. *Allergy Asthma Proc*. 2016;37:43-49.
 35. Hofer H, Asam C, Hauser M, et al. Tackling Bet v 1 and associated food allergies with a single hybrid protein. *J Allergy Clin Immunol*. 2017;140:525-533.e10.
 36. Westman M, Lupinek C, Bousquet J, et al. Early childhood IgE reactivity to pathogenesis-related class 10 proteins predicts allergic rhinitis in adolescence. *J Allergy Clin Immunol*. 2015;135:1199-1206.e11.
 37. Garcia-Aymerich J, Benet M, Saeys Y, et al. Phenotyping asthma, rhinitis and eczema in MeDALL population-based birth cohorts: an allergic comorbidity cluster. *Allergy*. 2015;70:973-984.
 38. González-Mancebo E, Domínguez-Ortega J, Blanco-Bermejo S, et al. Comparison of two diagnostic techniques, skin-prick test and component resolved diagnosis in the follow-up of a cohort of paediatric patients with pollinosis. Multicentre pilot study in a highly exposed allergenic area. *Allergol Immunopathol (Madr)*. 2017;45:121-126.
 39. Wickman M, Asarnoj A, Tillander H, et al. Childhood-to-adolescence evolution of IgE antibodies to pollens and plant foods in the BAMSE cohort. *J Allergy Clin Immunol*. 2014;133:580-582.
 40. Stern DA, Lohman IC, Wright AL, Taussig LM, Martinez FD, Halonen M. Dynamic changes in sensitization to specific aeroallergens in children raised in a desert environment. *Clin Exp Allergy*. 2004;34:1563-1669.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Cipriani F, Tripodi S, Panetta V, et al; for the Italian Pediatric Allergy Network (I-PAN). Early molecular biomarkers predicting the evolution of allergic rhinitis and its comorbidities: A longitudinal multicenter study of a patient cohort. *Pediatr Allergy Immunol*. 2019;30:325–334. <https://doi.org/10.1111/pai.13036>

Supporting Information

Early molecular biomarkers predicting the evolution of allergic rhinitis and its comorbidities: a longitudinal multicenter study of a patient cohort.

Francesca Cipriani¹, Salvatore Tripodi², Valentina Panetta^{3,4}, Serena Perna⁴, Ekaterina Potapova⁴, Arianna Dondi^{4,5}, Roberto Bernardini⁶, Carlo Caffarelli⁷, Antonella Casani⁸, Rosa Cervone⁶, Loredana Chini⁹, Pasquale Comberiati^{10,11}, Giovanna De Castro¹², Michele Miraglia Del Giudice¹³, Iride Dello Iacono¹⁴, Andrea Di Rienzo Businco², Marcella Gallucci¹, Arianna Giannetti¹, Carla Mastroianni^{4,7}, Viviana Moschese⁹, Simone Pelosi¹⁵, Ifigenia Sfika², Elena Varin¹⁶, Valeria Vilella², Anna Maria Zicari¹², Giulia Brindisi¹², Giampaolo Ricci¹, and Paolo Maria Matricardi⁴ for the Italian Pediatric Allergy Network (I-PAN).

1. Pediatric Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy;
2. Pediatric Department and Pediatric Allergology Unit, Sandro Pertini Hospital, Rome, Italy;
3. L'altrastatistica srl, Consultancy & Training, Biostatistics, Rome, Italy;
4. Department of Pediatric Pneumology and Immunology, Charite Medical University, Berlin, Germany;
5. Pediatric Emergency Unit, S. Orsola-Malpighi Hospital, Bologna, Italy;
6. Pediatric Unit, San Giuseppe Hospital, Empoli, Italy;
7. Clinica Pediatrica, Department of Medicine and Surgery, University of Parma, Parma, Italy;
8. Pediatra di Libera Scelta, Benevento, Italy;
9. UOSD di Immunopatologia ed Allergologia Pediatrica, Policlinico Tor Vergata, Università di Roma Tor Vergata, Rome, Italy;
10. Department of Clinical and Experimental Medicine, Section of Paediatrics, University of Pisa, Pisa, Italy;
11. Department of Clinical Immunology and Allergology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia;
12. Pediatric Department, La Sapienza University, Rome, Italy;
13. Dipartimento della Donna, del Bambino e di Chirurgia Generale e Specialistica, Università della Campania Luigi Vanvitelli, Naples, Italy;
14. Pediatric Unit, Fatebenefratelli Hospital, Benevento, Italy;
15. TPS Production, Rome, Italy;
16. Pediatric Intermediate Care Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Corresponding Author:

Giampaolo Ricci
Pediatric Unit, Dept. of Medical and Surgical Sciences
S. Orsola Malpighi Hospital - University of Bologna
Via Massarenti, 11
40138 Bologna – Italy
E-mail: giampaolo.ricci@unibo.it

Tables: 5

Table S1. Characteristics of the patients included and not included in the follow-up study among 1024 patients recruited for the baseline study.

	Included N=401	Not included N=623	<i>p value</i>
Males (n, %)	258 (64.3)	429 (69.0)	0.124
Age (years) (mean, SD)	10.4 (3.4)	10.5 (3.4)	0.907
Geographic area of Italy			<0.001
North (n, %)	193 (48.1)	179 (28.7)	
Center (n, %)	142 (35.4)	299 (48.0)	
South and islands (n, %)	66 (16.5)	145 (23.3)	
Familial atopy			
Father (n, %)	180 (44.9)	228 (36.6)	0.008
Mother (n, %)	157 (39.2)	265 (42.5)	0.283
Allergic rhinitis age at onset (years) (mean, SD)	5.2 (2.8)	5.2 (2.9)	0.348
Asthma* (n, %)	147 (36.7)	237 (38.0)	0.655
Oral allergy syndrome** (n, %)	94 (24.4)	157 (25.2)	0.523
Other food-related allergic symptoms** (n, %)	129 (32.2)	138 (22.2)	<0.001
Anaphylaxis (n, %)	21 (5.2)	34 (5.5)	0.879
Urticaria/angioedema (n, %)	93 (23.2)	109 (17.5)	0.025
Gastrointestinal symptoms (n, %)	41 (10.2)	36 (5.8)	0.008

* Doctor-diagnosed Asthma;

** Doctor-diagnosed Oral allergy syndrome or other food-related allergic symptoms.

Table S2. Atopic sensitization to indoor allergens at baseline and follow-up in 401 patients included in the study.

Allergen	Baseline	Follow-up	<i>p</i> value*
D. pteronyssinus** (%)	49.6	51.9	0.323
Alternaria** (%)	36.9	36.2	0.701
Cat** (%)	34.9	45.1	<0.001
Overall Indoor allergens (mean, SD)	1.2 ± 0.9	1.3 ± 0.9	0.004°
Pollens^ + indoor allergens** > 4 (%)	70.8	70.6	0.596

**p* value is referred to the percentage of patients with wheal diameter ≥ 3 mm, except for ° that are referred to mean number of positive SPT.

** Sensitization at baseline was assessed by IgE sensitization (ImmunoCAP FEIA; Phadia, Uppsala, Sweden) (sIgE > 0.35 kU/L were considered positive), while at follow-up by SPT to indoor extracts (wheal diameter ≥ 3 mm were considered as positive).

^ Number of positive skin reactions to pollens (wheal ≥ 3 mm). SPT extracts included: grass pollen (*P. pratense* or *C. dactylon*), *B. verrucosa*, *C. arizonica*, *P. acerifolia*, *O. europaea*, *P. judaica*, Compositae pollen (*A. vulgaris* or *A. artemisiifolia*), *P. lanceolata*, *S. kali*, *C. avellana*, *C. album*.

Table S3. Clinical characteristic and sensitization to airborne allergens at baseline in patients with remittent or persistent allergic rhinitis at follow-up among 401 patients with pollen-induced allergic rhinoconjunctivitis.

	Pollen-induced allergic rhinitis (N=401)					
	Remittent (N=27)		Persistent (N=374)		OR (CI 95%)	p value
Males (N, %)	16	59.3	242	64.7	1.26 (0.57-2.80)	0.569
Age at onset (years) (mean, SD)	5.1	2.7	5.3	2.8	0.91 (0.81-1.03)	0.75
Months/year with symptoms (mean, SD)	4.3	1.3	4,0	1.8	0.83 (0.37-1.84)	0.404
Asthma (N, %)	11	40.7	136	36.4	0.83 (0.38-1.84)	0.649
Oral Allergy Syndrome (N, %)	7	25.9	87	23.3	0.87 (0.35-2.12)	0.752
SPT PHL positive ≥ 3 mm	22	81.5	351	93.9	3.47 (1.20-10.00)	0.021
N Pollen allergens ≥ 3 mm (mean, SD)*	4.2	2.6	5.5	2.8	1.20 (1.02-1.41)	0.029
Overall indoor allergens (mean, SD)	1.3	0.9	1.2	0.9	0.95 (0.62-1.44)	0.795
Pollen allergens >4 (N, %)*	12	50,0	201	59.8	1.49 (0.65-3.41)	0.347
Pollens + indoor allergens >4 (N, %)*	12	50,0	243	72.3	2.61 (1.13-6.02)	0.024
Total IgE baseline (Ui/mL) (geometric mean, SD)***	298.9	4.1	403.4	3,0	1.24 (0.87-1.77)	0.225
Phl p molecules at baseline (mean, SD)**	3,0	2.1	3.8	2.1	1.22 (0.98-1.50)	0.069
sIgE to rPhl p 1 ≥ 0.35 kU/L (N, %)	18	66.7	321	85.8	3.03 (1.29-7.09)	0.011
sIgE to rPhl p 5 ≥ 0.35 kU/L (N, %)	10	37,0	229	61.2	2.68 (1.20-6.03)	0.017
sIgE to rPhl p 7 ≥ 0.35 kU/L (N, %)	2	7.4	16	4.3	0.56 (0.12-2.57)	0.454
sIgE to rPhl p 12 ≥ 0.35 kU/L (N, %)	4	14.8	102	27.3	2.16 (0.73-6.39)	0.165
sIgE to Bet v 1 ≥ 0.35 kU/L (N, %)	9	33.3	105	28.1	0.78 (0.34-1.79)	0.559
sIgE to Pru p 3 ≥ 0.35 kU/L (N, %)	10	37,0	94	25.1	0.57 (0.25-1.29)	0.178

* Skin reactions to pollens (wheal ≥ 3 mm). SPT extracts included: grass pollen (*P. pratense* or *C. dactylon*), *B. verrucosa*, *C. arizonica*, *P. acerifolia*, *O. europaea*, *P. judaica*, Compositae pollen (*A. vulgaris* or *A. artemisiifolia*), *P. lanceolata*, *S. kali*, *C. avellana*, *C. album*.

** In patients with SPT reaction to *P. pratense* ≥ 3 mm at baseline.

*** OR calculated on log value

Table S4. Clinical characteristic and sensitization to airborne allergens at baseline in patients with or without asthma at baseline according to their clinical evolution at follow-up among 401 patients included in the follow-up study.

	Asthma at baseline (N=147)						Non Asthma at baseline (N=254)					
	Remittent (N=33)		Persistent (N=114)		OR (CI 95%)	p value	Absent (N=173)		Incident (N=81)		OR (CI 95%)	p value
Males (N, %)	20	60.6	70	61.4	1.03 (0.47-2.29)	0.934	109	63.0	59	72.8	1.57 (0.88-2.81)	0.124
Age at onset of AR (years) (mean, SD)	4	2.2	4.7	2.3	1.03 (0.91-1.16)	0.128	6	3.2	4.9	2.6	0.88 (0.80-0.97)	0.01
Months/year with AR symptoms (mean, SD)	4.8	1.7	4	1.8	0.81 (0.66-0.99)	0.041	4	1.6	3.9	1.8	0.93 (0.79-1.10)	0.388
Oral Allergy Syndrome (N, %)	8	24.2	29	25.4	1.07 (0.43-2.62)	0.889	37	21.4	20	24.7	1.21 (0.65-2.25)	0.557
SPT PHL positive ≥ 3 mm (N, %)	30	90.9	110	96.5	2.75 (0.58-12.96)	0.201	157	90.8	76	93.8	1.55 (0.55-4.38)	0.41
N Pollen allergens ≥ 3 mm (mean, SD)*	5.1	2.7	5.8	2.7	1.10 (0.94-1.29)	0.225	5.0	2.9	5.8	2.7	1.10 (1.00-1.21)	0.052
Overall indoor allergens (mean, SD)	1.2	0.9	1.4	0.9	1.25 (0.82-1.91)	0.305	1	0.9	1.3	1.0	1.44 (1.07-1.92)	0.014
Pollen allergens >4 (N, %)*	15	53.6	72	69.9	2.01 (0.86-4.73)	0.108	77	50.7	49	63.6	1.70 (0.97-2.99)	0.063
Pollens + indoor allergens >4 (N, %)*	18	64.3	80	77.7	1.93 (0.78-4.76)	0.152	97	63.8	60	77.9	2.00 (1.06-3.77)	0.031
Total IgE baseline (Ui/mL) (geometric mean, SD)***	492.7	3.0	365	2.2	1.26 (0.87-1.83)	0.228	270.4	3.0	544.8	3.8	1.73 (1.33-2.25)	<0.001
Phl p molecules at baseline (mean, SD)**	3.1	1.9	4.1	2.2	1.26 (1.03-1.53)	0.024	3.5	2.1	3.9	2.0	1.09 (0.96-1.25)	0.184
sIgE to rPhl p 1 ≥ 0.35 kU/L (N, %)	28	84.8	100	87.7	1.28 (0.42-3.85)	0.666	139	80.3	72	88.9	1.96 (0.89-4.30)	0.095
sIgE to rPhl p 5 ≥ 0.35 kU/L (N, %)	16	48.5	77	67.5	2.21 (1.01-4.86)	0.048	94	54.3	52	64.5	1.51 (0.87-2.60)	0.139
sIgE to rPhl p 7 ≥ 0.35 kU/L (N, %)	2	6.1	11	9.6	1.66 (0.35-7.87)	0.526	2	1.2	3	3.7	3.29 (0.54-20.08)	0.197
sIgE to rPhl p 12 ≥ 0.35 kU/L (N, %)	7	21.2	34	29.8	1.58 (0.63-3.98)	0.334	44	25.4	21	25.9	1.03 (0.56-1.88)	0.933
sIgE to Bet v 1 ≥ 0.35 kU/L (N, %)	9	27.3	43	37.7	1.61 (0.69-3.79)	0.272	38	22.0	24	29.6	1.50 (0.82-2.72)	0.186
sIgE to Pru p 3 ≥ 0.35 kU/L (N, %)	11	33.3	34	29.8	0.85 (0.37-1.94)	0.7	31	17.9	28	34.6	2.42 (1.33-4.41)	0.004

*Skin reactions to pollens (wheal ≥ 3 mm). SPT extracts included: grass pollen (*P. pratense* or *C. dactylon*), *B. verrucosa*, *C. arizonica*, *P. acerifolia*, *O. europaea*, *P. judaica*, *Compositae* pollen (*A. vulgaris* or *A. artemisiifolia*), *P. lanceolata*, *S. kali*, *C. avellana*, *C. album*.

** In patients with SPT reaction to *P. pratense* ≥ 3 mm at baseline.

*** OR calculated on log value

Table S5. Clinical characteristic and sensitization to airborne allergens at baseline in patients with or without oral allergy syndrome at baseline according to their clinical evolution at follow-up among 401 patients included in the follow-up study.

	OAS at baseline (N=94)						Non OAS at baseline (N=307)					
	Remittent (N=31)		Persistent (N=63)		OR (CI 95%)	p value	Absent (N=219)		Incident (N=88)		OR (CI 95%)	p value
Males (N, %)	22	71,0	30	47.6	0.37 (0.15-0.93)	0.035	147	67.1	59	67,0	1.00 (0.59-1.69)	0.99
Age at onset of AR (years) (mean, SD)	5.3	3.4	5.2	3.2	0.99 (0.87-1.14)	0.923	5.3	2.7	5.1	2.8	0.97 (0.89-1.07)	0.568
Months/year with AR symptoms (mean, SD)	3.6	1.4	4.4	2,0	1.33 (1.00-1.76)	0.047	4.1	1.7	4	1.7	0.99 (0.85-1.15)	0.898
Asthma (N, %)	6	19.4	31	49.2	4.04 (1.46-11.18)	0.007	74	33.8	36	40.9	1.36 (0.82-2.26)	0.24
SPT PHL positive ≥ 3 mm (N, %)	29	93.5	62	98.4	4.28 (0.37-49.09)	0.243	202	92.2	80	90.9	0.84 (0.35-2.03)	0.701
N Pollen allergens ≥ 3 mm (mean, SD)*	6	3.1	6.9	2.5	1.14 (0.95-1.35)	0.152	4.9	2.7	5.5	2.7	1.08 (0.98-1.18)	0.132
Overall indoor allergens (mean, SD)	1.3	0.8	1.4	1,0	1.11 (0.70-1.77)	0.657	1.1	0.9	1.3	1.1	1.18 (0.90-1.54)	0.235
Pollen allergens >4 (N, %)*	17	63,0	42	80.8	2.47 (0.87-7.00)	0.089	102	51.3	52	63.4	1.65 (0.97-2.80)	0.064
Pollens + indoor allergens >4 (N, %)*	22	81.5	47	90.4	2.14 (0.56-8.15)	0.267	124	62.3	62	75.6	1.87(1.05-3.35)	0.034
Total IgE baseline (Ui/mL) (geometric mean, SD)***	445.9	3,0	492.7	2.5	1.02 (0.65-1.58)	0.945	365.3	3,0	403.4	3,0	1.12 (0.90-1.39)	0.321
Phl p molecules at baseline (mean, SD)**	3.3	1.9	3.9	2,0	1.17 (0.93-1.47)	0.182	3.8	2.1	3.6	2.3	0.96 (0.85-1.08)	0.505
sIgE to rPhl p 1 ≥ 0.35 kU/L (N, %)	26	83.9	58	92.1	2.23 (0.59-8.38)	0.235	186	84.9	69	78.4	0.64 (0.34-1.21)	0.17
sIgE to rPhl p 5 ≥ 0.35 kU/L (N, %)	16	51.6	44	69.8	2.17 (0.89-5.27)	0.087	131	59.8	48	54.4	0.81 (0.49-1.33)	0.397
sIgE to rPhl p 7 ≥ 0.35 kU/L (N, %)	0	0	4	6.3	4.76 (0.18-128.43)	0.353	13	5.9	1	1.1	0.18 (0.02-1.41)	0.103
sIgE to rPhl p 12 ≥ 0.35 kU/L (N, %)	8	25.8	18	28.6	1.15 (0.43-3.04)	0.778	56	25.6	24	27.3	1.09 (0.62-1.91)	0.759
sIgE to Bet v 1 ≥ 0.35 kU/L (N, %)	5	16.1	31	49.2	5.04 (1.72-14.79)	0.003	50	22.8	28	31.8	1.58 (0.91-2.73)	0.103
sIgE to Pru p 3 ≥ 0.35 kU/L (N, %)	12	38.7	23	36.5	0.91 (0.38-2.21)	0.836	45	20.5	24	27.3	1.45 (0.82-2.57)	0.203

* Skin reactions to pollens (wheal ≥ 3 mm). SPT extracts included: grass pollen (*P. pratense* or *C. dactylon*), *B. verrucosa*, *C. arizonica*, *P. acerifolia*, *O. europaea*, *P. judaica*, *Compositae pollen* (*A. vulgaris* or *A. artemisiifolia*), *P. lanceolata*, *S. kali*, *C. avellana*, *C. album*.

** In patients with SPT reaction to *P. pratense* ≥ 3 mm at baseline.

*** OR calculated on log value